Skip to main content
PFE
NYSE Life Sciences

Florida AG Sues Pfizer Over COVID Vaccine Claims, Seeks Fines and Disgorgement

Tom Rudovsky · Reported by Wiseek News
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$28.12
Mkt Cap
$160.275B
52W Low
$23.62
52W High
$29.21
52W Position info
19% above low
Off High info
3.7% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PFE sits 19% above its 52-week low of $23.62.

Summary

Florida Attorney General James Uthmeier is leading a lawsuit against Pfizer and its CEO Albert Bourla, alleging violations of the Florida Deceptive and Unfair Trade Practices Act over misstatements about COVID-19 vaccine efficacy and safety. The complaint seeks fines, disgorgement, and injunctive relief, and cites a 2023 price increase to $110-$130 per dose. It alleges Pfizer spent over $10 billion on advertising from 2020 to 2023, generating over $80 billion in vaccine sales, while Bourla earned nearly $102 million in compensation supplemented by stock profits and book sales. The lawsuit claims hidden safety risks including links to myocarditis and pericarditis in minors, strokes, elderly fatalities, and adverse events for pregnant women including miscarriages, which were discussed among Anthony Fauci, Surgeon General Vivek Murthy, and CDC Director Rochelle Walensky. It also alleges Pfizer never tested the vaccine's effect on transmission, that Bourla publicly declared no safety signal had been observed, and that Pfizer pressured consumers by asserting mass vaccination was a moral duty and branded skeptics as criminals. Pfizer disputes the claims. This legal action adds regulatory and reputational risk to a company already facing scrutiny over vaccine contracts and pricing, and may weigh on sentiment despite positive Phase 2 data for tilrekimig in atopic dermatitis.

Updated with a Benzinga report · What changed

Updates

  1. · Benzinga — The lawsuit alleges Pfizer spent over $10 billion on advertising from 2020 to 2023, generating over $80 billion in vaccine sales, and that CEO Albert Bourla earned nearly $102 million in compensation.

    • Allegations — Florida Attorney General James Uthmeier is leading the lawsuit, which alleges Pfizer violated the Florida Deceptive and Unfair Trade Practices Act.
    • Safety Risks — Alleged hidden safety risks include links to myocarditis and pericarditis in minors, strokes, elderly fatalities, and adverse events for pregnant women including miscarriages, which were discussed among Anthony Fauci, Surgeon General Vivek Murthy, and CDC Director Rochelle Walensky.
    • Transmission Testing — The lawsuit claims Pfizer never tested the vaccine's effect on transmission.
    • Public Statements — Bourla publicly declared no safety signal had been observed, and Pfizer pressured consumers by asserting mass vaccination was a moral duty and branded skeptics as criminals.
    • Compensation — CEO Albert Bourla's compensation was supplemented by stock profits and book sales.
    All 10 details
    • Florida Attorney General James Uthmeier is leading the lawsuit.
    • The lawsuit alleges Pfizer violated the Florida Deceptive and Unfair Trade Practices Act.
    • CEO Albert Bourla's compensation was supplemented by stock profits and book sales.
    • Alleged hidden safety risks include links to myocarditis and pericarditis in minors, strokes, and elderly fatalities.
    • Alleged hidden safety risks include concerns over adverse events for pregnant women, including miscarriages.
    • The lawsuit claims Pfizer never tested the vaccine's effect on transmission.
    • Bourla publicly declared that the company had not observed a single safety signal.
    • Pfizer pressured consumers by asserting that mass vaccination was a moral duty required to prevent transmitting the virus to loved ones.
    • Pfizer actively worked to quash opposition by branding skeptics as criminals.
    • Concerns over adverse events for pregnant women, including miscarriages, were discussed among Anthony Fauci, Surgeon General Vivek Murthy, and CDC Director Rochelle Walensky.

At the time of this announcement, PFE was trading at $28.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $160.3B. The 52-week trading range was $23.62 to $29.21. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $29.90 info
Change: -$0.7594 (-2%) info
Market Cap: $170.312B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $29.90 info
Change: -$0.7248 (-2%) info
Market Cap: $170.312B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $29.90 info
Change: -$0.830 (-3%) info
Market Cap: $170.312B info
PFE
Nov 03, 2026, 6:45 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $29.90 info
Change: -$1.08 (-3%) info
Market Cap: $170.312B info
PFE
Oct 27, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.77
Real-time Price: $29.90 info
Change: +$0.130 (+0.44%) info
Market Cap: $170.312B info